ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 538

Association Between Biomarkers (Metalloproteinase-3, Dikkopf-1 and Sclerostin) with Disease Activity and Prediction of Anti-TNFá Therapy Response in Patients with Ankylosing Spondylitis

Victoria Navarro-Compán1, Rafael Ariza2, Rufino Mondéjar-García3, Virginia Moreira-Navarrete4, Enrique Melguizo-Madrid3, Blanca Hernández-Cruz4, Concepción González-Rodríguez3 and Federico Navarro-Sarabia5, 1Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, University Hospital Virgen Macarena.Sevilla, Sevilla, Spain, 3Biochemistry, University Hospital Virgen Macarena, Sevilla, Spain, 4Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, 5Rheumatology, Hospital Virgen Macarena, Serv. de Reumatología, Sevilla, Spain

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), anti-TNF therapy and biomarkers

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: Better objectives measures for evaluating disease activity and anti-TNFα response in patients with ankylosing spondylitis (AS) are needed. MMP-3 seems to be the most promising biomarker but published data are not conclusive. The aim of this study was to investigate the association between serum biomarkers (MMP-3, DKK-1 and sclerostin) levels with disease activity parameters and to evaluate if these biomarkers are useful to predict anti-TNFα response in patients with AS.


Methods: From November 2010 to July 2011, consecutive patients with AS (New York criteria) who initiated anti-TNFα therapy in a University hospital were included. Before and after 3 months of therapy, disease activity was measured using BASDAI, ASDAScrp, CRP, patient’s VAS of pain and patient’s and physician’s VAS of global disease activity (GDA). Blood samples for determination of serum levels of biomarkers by enzyme immunoassay were also collected at both visits.
Spearman correlation test was used to evaluate association between biomarkers and disease activity parameters. Biomarkers change was compared in responders versus non-responders, based on BASDAI50 and ASDAS response using Mann-Whitney U test. Accuracy to predict response (ROC analysis) was performed.


Results:
Twenty AS patients were included; 80% received adalimumab and 20% received etanercept. Median (IQR) age and disease duration were 42.4 (31-49) years and 6.8 (3-10) years, respectively; 86% were men, and 83% HLA-B27 positive. Inverse correlation between patient’s VAS pain and MMP-3 at baseline was the only significant observed correlation between investigated biomarkers and disease activity parameters (table 1).  MMP-3 levels decreased only in patients who responded to anti-TNF therapy but increased in patients who did not response (table 2). Baseline biomarkers serum levels (including CRP) for both groups were similar except for MMP-3 (122.9 vs 58.9; p<0.05). The area under the curve for MMP-3 to predict BASDAI50 and ASDAS response was 0.73 and 0.78, respectively. The best cut-off was established for levels higher than 59.5, with sensibility of 79-85% and specificity of 50-57%.

 

Conclusion: No correlation was observed between serum levels of MMP-3, DKK-1 and sclerostin and disease activity parameters in patients with AS. Serum levels of MMP-3 may be useful to predict response to anti-TNFα therapy in patients with AS.

 

 

 

 

 

 

 

 

 

 

 

Table 1: Correlation between serum levels of biomarkers with disease activity parameters.

 

 

BASDAI

ASDAScrp

Pt GDA

Pt VAS pain

Phy GDA

CRP

At baseline

 

 

 

 

 

 

   MMP-3

-0.318

-0.086     

-0.334

 -0.477*

-0.551

0.222

   DKK-1

-0.017

-0.045

 0.003

 0.149

 0.234

0.107

   SOST

-0.096

-0.039

-0.074

 0.066

-0.154

0.002

   CRP

-0.288

   0.577**

 0.122

 0.039

 0.032

1.000

After 3 months

 

 

 

 

 

 

   MMP-3

-0.135

-0.144

-0.169

-0.154

-0.156

-0.024

   DKK-1

-0.007

 0.168

 0.155

 0.179

 0.270

 0.296

   SOST

-0.006

 0.114

 0.306

 0.166

 0.427

 0.172

   CRP

 0.003

   0.457*

 0.177

 0.173

 0.266

 1.000

              * p<0.05 ** p<0.01

 

 

 

Table 2: Change in serum levels of MMP-3, DKK-1, sclerostin and CRP after 3 months of anti-TNFα therapy based on the clinical response.

 

 

Responders

N=13 (65%)

Non-responders

N=7 (35%)

 

Baseline

3 months

p

Baseline

3 months

p

MMP-3 (ng/dl)

122.2

64.1

0.01

58.9

75.5

0.6

DKK-1 (ng/dl)

6.9

8.1

0.6

7.3

6.7

0.6

SOST (pmol/dl)

23.6

23.4

0.9

18.1

21.3

0.2

CRP    (mg/l)

16.3

4.0

0.002

8.3

5.3

0.3

 


Disclosure:

V. Navarro-Compán,
None;

R. Ariza,
None;

R. Mondéjar-García,
None;

V. Moreira-Navarrete,
None;

E. Melguizo-Madrid,
None;

B. Hernández-Cruz,
None;

C. González-Rodríguez,
None;

F. Navarro-Sarabia,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-biomarkers-metalloproteinase-3-dikkopf-1-and-sclerostin-with-disease-activity-and-prediction-of-anti-tnfa-therapy-response-in-patients-with-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology